Article

FDA grants Vitrase 5 years' exclusivity

The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Related Content
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA
July 26th 2025

Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
July 25th 2025

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
July 24th 2025

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Kiora Pharmaceuticals Secures US Patent for KIO-104
July 24th 2025

Kiora Pharmaceuticals Secures US Patent for KIO-104

© 2025 MJH Life Sciences

All rights reserved.